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Background: High-sensitivity troponin T (hs-TnT) emerged as a robust predictor of prognosis in 
stable chronic heart failure (HF) in an individual patient data meta-analysis. In the same population, 
we compared the predictive performances of hs-TnT, pro-B-type natriuretic peptide N-terminal 
fraction (NT-proBNP), hs-C-reactive protein (hs-CRP), and estimated glomerular filtration rate 
(eGFR).  
Methods and Results: 9289 patients (66±12 years, 77% men, 85% LVEF <40%, 60% ischemic 
HF) were evaluated over a 2.4-year median follow-up. Median eGFR was 58 mL/min/1.73 m2 
(interquartile interval 46-70; n=9220), hs-TnT 16 ng/L (8-20; n=9289), NT-proBNP 1067 ng/L 
(433-2470; n=8845), and hs-CRP 3.3 mg/L (1.4-7.8; n=7083). In a model including all 3 
biomarkers, only hs-TnT and NT-proBNP were independent predictors of all-cause and 
cardiovascular mortality and cardiovascular hospitalization. hs-TnT was a stronger predictor than 
NT-proBNP: for example, the a risk for all-cause death increased by 54% per doubling of hs-TnT 
vs. 24% per doubling of NT-proBNP. eGFR showed independent prognostic value from both hs-
TnT and NT-proBNP. The best hs-TnT and NT-proBNP cut-offs for the prediction of all-cause 
death increased progressively with declining renal function (eGFR ≥90: hs-TnT 13 ng/L and NT-
proBNP 825 ng/L; eGFR <30: hs-TnT 40 ng/L and NT-proBNP 4608 ng/L). Patient categorization 
according to these cut-offs effectively stratified patient prognosis for the 3 endpoints across all 
eGFR classes. 
Conclusions: hs-TnT conveys independent prognostic information from NT-proBNP, while hs-
CRP does not. Concomitant assessment of eGFR may further refine risk stratification. Patient 
classification according to hs-TnT and NT-proBNP cut-offs specific for the eGFR classes holds 
prognostic significance.  
 
 




Heart failure (HF) is a highly prevalent disease condition, and a leading cause of morbidity and 
mortality worldwide.[1] Accurate risk prediction allows to tailor HF treatment and follow-up 
strategy in the individual patient, possibly resulting in better quality of life and long-term 
prognosis.[2] Many predictors of death and/or HF-related hospitalization have been identified, 
although their applicability in common clinical practice is often limited, and precise risk 
stratification in HF remains challenging.[2]  
Cardiac biomarkers are gaining increasing recognition as tools for risk prediction in HF.[3] In 
particular, the American Heart Association/American College of Cardiology Foundation has issued 
a class I, level of evidence A recommendation for the assessment of B-type natriuretic peptide 
(BNP) or the N-terminal fraction of pro-BNP (NT-proBNP) for prognostic stratification in chronic 
HF.[4] Furthermore, troponin elevation is a frequent finding in chronic HF, and has been 
established in several studies as a predictor of adverse outcome.[5] In a recent meta-analysis 
concerning 9289 individual patient data (IPD) from 11 cohorts, we confirmed a strong prognostic 
value of high-sensitivity (hs) TnT assay for all-cause death, cardiovascular death, and 
cardiovascular hospitalization, additive to established risk markers (sex, age, ischemic vs. non-
ischemic etiology, left ventricular ejection fraction - LVEF, estimated glomerular filtration rate - 
eGFR, and also NT-proBNP). [6]   
The mechanisms leading to the production and release of natriuretic peptides in HF include 
hemodynamic overload and neurohormonal activation, while troponin elevation is driven by 
ongoing cardiomyocyte necrosis/apoptosis.[7] Other biomarkers could contribute to refine risk 
stratification: in particular, a subclinical myocardial inflammation is frequently observed in HF and 
hs-C-reactive protein (hs-CRP) carries prognostic significance in chronic HF.[8-10] Furthermore, 
chronic kidney disease is a common comorbidity in chronic HF, with an established prognostic 




We felt it worthwhile to compare the prognostic performances of NT-proBNP, hs-TnT, hs-CRP, 
and eGFR, and to evaluate a multi-biomarker strategy for risk stratification in chronic HF in the 
largest IPD database currently available.  
 
Methods 
Search study, study selection 
The design and main results of our IPD meta-analysis on hs-TnT in CHF have been reported in 
detail.[6] Briefly, in April 2017, two authors (AA and GV) independently searched 4 databases 
(Medline, EMBASE, Cochrane Library, and Scopus), using the following search terms: “troponin” 
AND “heart failure” OR “cardiac failure” OR “cardiac dysfunction” OR “cardiac insufficiency” OR 
“left ventricular dysfunction”. The inclusion criteria were: English language; patients aged ≥18 
years and diagnosed with HF; reported enrolment of outpatients or patients undergoing elective 
admission; reported use of a hs-TnT and/or I assay; information on patient prognosis; authors’ 
availability to provide IPD data. These last corresponded to as many as possible of the following 
variables: age, sex, ethnic group, body-mass index, comorbidities (hypertension, atrial fibrillation, 
diabetes mellitus, chronic obstructive pulmonary disease), plasma hemoglobin, HF etiology 
(ischemic vs. non-ischemic), LVEF, hs-TnT and/or I, NPs, serum creatinine, hs-CRP), follow-up 
duration, and outcome measures (all-cause death, cardiovascular death, and hospitalization for 
cardiovascular cause).[6] 
Ten studies met all these requirements, reporting data on 11 cohorts, with a total patient number 
of 9289.[13-22] Since hs-TnI values were available for a small minority of patients,[8] only hs-TnT 
was considered. Five other studies, including a total patient number of 1312, could not be included 





For the present analysis, the IBM SPSS Statistics (version 22, 2013) and R statistical software 
(http://www.r-project.org/, version 3.4.0) were used. Normal distribution was assessed through the 
Kolmogorov-Smirnov test; variables with normal distribution were presented as mean±standard 
deviation, while those with non-normal distribution as median and interquartile interval. Mean 
differences among groups were evaluated through the unpaired Student T test. Pearson’s product 
moment correlation coefficient (r) was calculated as a measure of linear association between 
normally distributed variables. 
For all the following analyses, NT-proBNP, hs-TnT, hs-CRP, and eGFR were log2-transformed to 
account for non-normal distribution. Pearson's product moment correlation coefficient quantified 
the strength of correlation between normally distributed variables. Categorical variables were 
compared by the Chi-square test with Yates correction. The log-rank test (Mantel-Cox) was used to 
compare survival times on Kaplan-Meier curves. The optimal cut-offs for ROC curves were 
established by Youden’s J statistic. At discrimination analysis, the AUC values were compared 
through the De Long’s test. The D’Agostino-Nam version of the Hosmer-Lemeshow calibration test 
was used to calculate χ2 values as measure of calibration. The net reclassification improvement 
(with risk categories set at <10%, 10-30% and >30%) and the integrated discrimination 
improvement were calculated to assess reclassification. Univariate and multivariate Cox regression 
analyses allowed to identify predictors of outcome. Multicollinearity (i.e. interference among 
variables included into a multivariable prognostic model) was assessed by calculating the Variance 
Inflation Factor (VIF). The Fine-Gray model was used to account for mutually exclusive endpoints; 
non-cardiovascular death was considered as competing risk for cardiovascular death, and all-cause 







The main characteristics of the 9289 patients, divided into their cohorts, are reported in Table 1. 
Overall, patients were aged 66±12 years, and were more often males (n=7122, 77%). The majority 
of patients had HF with reduced ejection fraction (LVEF <40%: n=7902, 85%; LVEF 40-49%: 
n=718, 8%;  LVEF ≥50%: n=479, 5%). All patients had available data on HF etiology; ischemic HF 
was more common (5543 patients, 60%). GFR, estimated from serum creatinine through the chronic 
kidney disease epidemiology collaboration (CKD-EPI) equation,[28] was available for 9220 
patients (99%); its median value was 58 mL/min/1.73 m2 (interquartile interval 46-70); patients on 
dialysis were not included in the original studies. Median follow-up duration was 2.4 years 
(interquartile interval 1.6-3.3). Data on all-cause death were available for all cohorts (2620 deaths, 
28%), whereas data on cardiovascular death were available for 6 cohorts (8487 patients, 1725 
events, 20%), and data on cardiovascular hospitalization for other 6 (8168 patients, 2375 events, 
29%) (Table 1). At 1 year, 888 all-cause deaths (10%), 676 (7%) cardiovascular deaths, and 343 
(4%) cardiovascular hospitalizations were recorded; at 5 years, these events were 2423 (26%), 1658 
(18%), and 2244 (24%), respectively.  
 
Circulating biomarker levels  
NT-proBNP levels were available for 8845 patients (95%; median 1067 ng/L, interquartile interval 
433-2470 ng/L). All patients had hs-TnT measured. In all studies was used the only available hs-
TnT assay (Roche Diagnostics®, Basel, Switzerland; lower detection limit of 3 ng/L, 99th percentile 
value in apparently healthy individuals of 14 ng/L).[29] Median value was 16 ng/L, with 8-20 ng/L 
interquartile interval. Finally, 7083 patients (83%) had hs-CRP data (median 3.3 mg/L, interquartile 
interval 1.4-7.8 mg/L).  
 
Biomarkers and prognosis 
When performing a comparative assessment of the prognostic performance of hs-TnT and other 
biomarkers, we found first that hs-TnT displayed higher AUC values than NT-proBNP for all 3 
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endpoints (all p values <0.001; Figure 1). Adding hs-TnT to NT-proBNP resulted in better 
discrimination and reclassification, compared to NT-proBNP alone, with a change in risk category 
in 28% of patients (Supplemental Table 1). These findings were confirmed in several population 
subsets (Supplemental Table 2). Adding hs-CRP to hs-TnT and NT-proBNP did not further 
improve risk prediction, compared to hs-TnT plus NT-proBNP (Supplemental Table 1). 
NT-proBNP, hs-TnT and hs-CRP were univariate predictors of outcome, but only NT-proBNP 
and hs-TnT remained independent predictors in a model including all 3 biomarkers (Table 2). hs-
TnT emerged as a stronger predictor of the 3 endpoints: for example, the risk for all-cause death 
increased by 54% per doubling of hs-TnT vs. 24% per doubling of NT-proBNP (Table 2). These 
findings were replicated across patient subgroups, categorized according to sex, age (≥ or <66 
years), etiology (ischemic or non-ischemic), LVEF (<40%, 40-49%, ≥50%), and eGFR (<30, 30-59, 
60-89, ≥90 mL/min/1.73 m2) (Supplemental Table 3).  
 
hs-TnT, NT-proBNP, renal function, and prognosis 
In a model including NT-proBNP and hs-TnT, eGFR was independent predictor of both all-cause 
(HR 0.72, 95% CI 0.65-0.81; p<0.001) and cardiovascular death (HR 0.76, 95% CI 0.67-0.86; 
p<0.001), but not of cardiovascular hospitalization (HR 0.97, 95% CI 0.87-1.08; p=0.591). The 
variables displayed significant correlations (Supplemental Table 4), but multicollinearity was 
excluded because of VIF=1.15 (reference value <10).[30]  
The best hs-TnT and NT-proBNP cut-offs for the prediction of the 3 endpoints increased with 
declining renal function (Table 3). At Kaplan-Meier analysis, patient classification according to 
these cut-offs proved effective in risk stratification across all eGFR categories. At baseline, hs-TnT 
and NT-proBNP were either both <cut-off or ≥cut-off in the majority of patients; these groups had 
the longest and the shortest survival, respectively (Figures 2-4), while discordant cases had an 
intermediate prognosis, with no significant differences between the two combinations 





In the largest cohort of patients with chronic HF so far assessed with this respect, NT-proBNP, hs-
TnT, and hs-CRP were univariate predictors of all-cause death, cardiovascular death, and 
cardiovascular hospitalization. Furthermore, hs-TnT appeared a stronger predictor of outcome than 
NT-proBNP, based on both HR and AUC values. hs-TnT had also independent prognostic value 
from NT-proBNP, while hs-CRP did not. Adding hs-TnT to NT-proBNP resulted in better 
discrimination and reclassification compared with NT-proBNP alone, with a change in risk category 
for substantial percentages of patients (all-cause death: 28%, cardiovascular death: 24%, and 
cardiovascular hospitalization: 26%). The combination of hs-CRP, hs-TnT and NT-proBNP did not 
further improve risk stratification over hs-TnT plus NT-proBNP. On the other hand, eGFR was 
independent predictor of all-cause and cardiovascular mortality in a model including NT-proBNP 
and hs-TnT. The best hs-TnT and NT-proBNP cut-offs for the prediction of all-cause death 
increased with decreasing eGFR, and patient classification according to these cut-offs proved 
effective in risk stratification across all eGFR categories.  
These results add to our previous report of an incremental prognostic value of hs-TnT, compared 
to a prognostic model including NT-proBNP (together with patient age, sex, ischemic etiology, 
LVEF, eGFR).[6] Interestingly, the same conclusions apply to patients with either ischemic or non-
ischemic etiologies, confirming the established notion that the correlates of HF progression are 
broadly similar after an ischemic or non-ischemic cardiac insult. Similarly, no differences were 
found across age groups, and there was no interaction with patient sex, although women with HF 
tend to have lower natriuretic peptides levels, and also lower troponin concentration.[31] Finally, 
despite the wide heterogeneity in disease mechanisms and clinical presentation, hs-TnT retained an 
additive prognostic value to NT-proBNP across all categories of systolic dysfunction, namely in the 
<40% and 40-49% LVEF intervals, as well as among patients with preserved systolic function 
(LVEF ≥50%), reasonably because the disease mechanisms explored are common to all these forms 
9 
 
of HF. Finally, circulating hs-TnT and NT-proBNP levels are increased in chronic kidney disease 
(CKD), because of neurohormonal activation associated with CKD, and contributing to cardiac 
damage,[32] and because of reduced renal clearance.[33] Nonetheless, hs-TnT retains independent 
prognostic value from NT-proBNP across all eGFR ranges. The best hs-TnT and NT-proBNP cut-
offs tend to increase with declining renal function, but patient categorization according to these cut-
offs results very effective for risk stratification. Indeed, patients with both biomarkers higher than or 
equal to the respective cut-offs have the worst prognosis, and those with both biomarkers below cut-
offs have the better prognosis; furthermore, the condition of only one biomarker ≥cut-off, denoting 
a moderate severity of ongoing myocardial damage, is associated with an intermediate prognosis.  
A recent study confirmed the independent prognostic value of hs-troponin assays (both T and I) 
compared to NT-proBNP in patients with either LVEF <50% or ≥50%, thus corroborating our 
conclusions, although in a much smaller population (n=1096), and with a shorter follow-up 
duration.[34] Notably, both median levels and AUC-defined hs-TnT cut-offs were higher than those 
we are reporting, possibly reflecting different inclusion criteria or the specific ethnic group assessed 
(61% Chinese patients, 27% Malay patients).[34] On the other hand, the consistency of the main 
results, i.e. that hs-TnT refines risk stratification when added to NT-proBNP, and that hs-TnT cut-
offs close to the upper reference limit are discriminator of prognosis, provide strong conceptual 
support to the combined assessment of NT-proBNP and hs-TnT for risk stratification of patients 
with chronic HF. In particular, the hs-TnT assay is commonly available because of its established 
role in the diagnosis and management of acute coronary syndromes.[35] The assay has been 
extensively validated, has limited costs, and is automated, allowing to reduce human workload and 
sample processing times.[29] Finally, result interpretation is straightforward, especially since the 18 
ng/L cut-off holds independent prognostic significance in the whole population, as well as in 
categories identified by patient sex, HF etiology, and eGFR classes (as demonstrated in our 
previous meta-analysis).[6] Overall, the hs-TnT assay seems to meet the prerequisites for 
widespread diffusion for risk stratification of stable chronic HF patients,[36] although dedicated 
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analyses should explore the balance between increased costs and prognostic benefit from combined 
NT-proBNP and hs-TnT evaluation. 
In the search for a multi-marker strategy for chronic HF, many circulating molecules have been 
evaluated in addition to natriuretic peptides and troponins. Among them there are soluble 
suppression of tumorigenesis-2 (sST2),[9,37] galectin-3,[10] growth-derived factor-15 (GDF-
15),[10] and hs-CRP as an indicator of inflammation. In particular, in the Val-HeFT cohort 
(included in our population), a relationship between hs-CRP quartiles and mortality was observed, 
the prognostic power of hs-CRP being independent of HF etiology and BNP.[38] In a small study 
on advanced chronic HF, not included in the meta-analysis because of no available individual 
patient data, hs-CRP was predictive over both NT-proBNP and hs-TnT.[10] In the present analysis, 
the majority of studies reporting data on hs-TnT considered also NT-proBNP and hs-CRP. This 
biomarker of inflammation was not an independent predictor of outcome or improved prognostic 
performance over hs-TnT plus NT-proBNP, possibly because of the link between myocardial 
necrosis and inflammation, reflecting in overlapping prognostic information. The same conclusion 
applied to several patient categories.  
Renal dysfunction has been identified as a predictor of prognosis in chronic HF, as previously 
reported in terms of serum creatinine >176 μmol/L,[39] lower creatinine clearance,[40] or lower 
eGFR.[12] Herein, we confirm that eGFR holds independent prognostic significance from NT-
proBNP and hs-TnT. Furthermore, we report that patient categorization according to NT-proBNP 
and hs-TnT has strong prognostic significance across eGFR categories in chronic HF.  
The present study is based on the data repository created for the meta-analysis on hs-TnT in 
chronic HF, and does not include papers published after April 2017, which are basically limited to a 
study presented in the Discussion, and which stands in agreement with our conclusions.[34] 
Because of limitations related to data collection, only NT-proBNP was evaluated, although the 
assessment of BNP would be interesting as well. The impact of comorbidities and drug or device 
therapies on the prognostic relevance of biomarkers remains to be elucidated, and the specific 
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setting of patients on dialysis was not evaluated. Furthermore, repeated biomarker evaluations were 
not considered, albeit potentially useful in order to further refine prognostic stratification. Finally, 
as stated above, dedicated studies should assess the cost-efficacy balance of a multi-marker 
assessment in HF outpatients.  
In conclusion, hs-TnT conveys prognostic information that is independent from NT-proBNP, 
while hs-CRP does not. Concomitant assessment of eGFR may further refine risk stratification. The 
best hs-TnT and NT-proBNP cut-offs for the prediction of all-cause death increased progressively 
with declining renal function. Patient categorization according to these cut-offs helped predict all-
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Figure 1. Biomarkers and prognosis in heart failure. 
Areas under the curve (AUC) for N-terminal fraction of pro-B-type natriuretic peptide (NT-
proBNP), high-sensitivity troponin T (hs-TnT), hs-C-reactive protein (hs-CRP), and their 
combination are represented. All biomarkers were log2-transformed. As reported in the text, p 
values for hs-TnT vs. either NT-proBNP or hs-CRP were both <0.001; hs-TnT vs. (hs-TnT+NT-
proBNP+hs-CRP), p<0.001 for all-cause and cardiovascular (CV) death, p=0.005 for cardiovascular 
hospitalization.  
 
Figure 2. Biomarker-based categorization for predicting all-cause mortality. 
eGFR, estimated glomerular filtration rate (expressed as mL/min/1.73 m2); NT, N-terminal fraction 
of pro-B-type natriuretic peptide; TnT, (high-sensitivity) troponin T. The numbers of patients at risk 
is reported in Supplemental Table 7. 
 
Figure 3. Biomarker-based categorization for predicting cardiovascular mortality. 
eGFR, estimated glomerular filtration rate (expressed as mL/min/1.73 m2); NT, N-terminal fraction 
of pro-B-type natriuretic peptide; TnT, (high-sensitivity) troponin T. The numbers of patients at risk 
is reported in Supplemental Table 7. 
 
Figure 4. Biomarker-based categorization for predicting cardiovascular hospitalization. 
eGFR, estimated glomerular filtration rate (expressed as mL/min/1.73 m2); NT, N-terminal fraction 
of pro-B-type natriuretic peptide; TnT, (high-sensitivity) troponin T. The numbers of patients at risk 
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